Compare BIO-TECHNE Corp (TECH) vs XPO Inc. Common Stock (XPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs XPO Inc. Common Stock — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while XPO Inc. Common Stock trades at $182.35 (market cap $21.30B). The key difference: XPO Inc. Common Stock is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while XPO Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and XPO Inc. Common Stock for 0 Days on average.
| TECH | XPO | |
|---|---|---|
Market Cap | $11.36B | $21.30B |
Volume | 5,390,331 | 897,705 |
Sector | Health | Industrials |
52-Week High | $72.61 | $228.37 |
52-Week Low | $43.31 | $123.66 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $11.39B | $24.99B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About XPO Inc. Common Stock
XPO provides freight transportation services in North America and Europe. Its operations include less-than-truckload freight transportation and brokerage services supported by a technology platform.
Read more on XPO →
